Refine by
Tumor Stroma Equipment & Supplies
5 equipment items found
Manufactured by:Virasoft Inc. based inSarıyer, TURKEY
Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, B cells, macrophages, dendritic cells, mast cells and healthy tissue cells. But PD-L1 can be expressed by tumor cells and tumor stroma. Interaction tumoral PD-L1 with PD-1 stimulates PD-1-mediated T cell inhibition and down regulation of immune ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB005 is an allogeneic CAR-T product which targets B7-H3 (also known as CD276). B7-H3 expression has been detected in a wide range of solid tumors including lung, breast, colorectal, liver and skin cancers. It has also been observed on tumor vasculature and stroma, has been hypothesized to be an immune checkpoint and to be expressed on cancer ...
Manufactured by:GeneCentric Therapeutics, Inc. based inDurham, NORTH CAROLINA (USA)
Pancreatic Cancer is the 11th most common cancer type with an estimated 55,000 new cases in the US in 2018, according to the United States National Cancer Institute. While it represents three percent of all cancers, pancreatic cancer is one of the most lethal as it is so difficult to detect in early stages, accounting for seven percent of all cancer deaths and carrying among the lowest five ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic ...